Xuehan Lu

Ms. Xuehan Lu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
Lantian LuLantian Lu
Lantian Lu
XLXuehan Lu
Xuehan Lu
WLWei Luo
Wei Luo
Personalized cancer vaccines represent a revolutionary frontier in oncology, harnessing the unique genetic and molecular profile of individual tumors to elicit targeted immune responses. This review provides a comprehensive overview of the current landscape and future perspectives of neoantigen-based personalized cancer vaccines, encompassing peptide, mRNA, DNA, autologous dendritic cell, and viral or bacterial vector platforms. We further discuss the integration of immune adjuvants, delivery systems, and combinational strategies, particularly with immune checkpoint inhibitions, to overcome tumor-induced immune exhaustion and improve therapeutic efficacy. Despite significant clinical progress over the past decade in this space, major challenges remain in immunogenic neoantigens prediction, streamlining individualized vaccine manufacturing, and optimization of combinational regimens to maximize durable antitumor responses. By reviewing recent preclinical and clinical studies on neoantigen-based cancer vaccines, this review highlights key advances, identifies persistent translational bottlenecks, and underscores the need for biomarker-guided mechanistically informed trials to fully unleash the clinical potential of neoantigen-based personalized cancer vaccines in the era of precision immuno-oncology.

29 December 2022 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
MLMengfei Li
Mengfei Li
HCHongyu Chen
Hongyu Chen
DPDingchuan Peng
Dingchuan Peng
XLXuehan Lu
Xuehan Lu
JKJianping Kong
Jianping Kong
YWYing Wang
Ying Wang

13 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DSDebottam Sinha
Debottam Sinha
PMPhilip Moseley
Philip Moseley
XLXuehan Lu
Xuehan Lu
QWQuentin Wright
Quentin Wright
Brian GabrielliBrian Gabrielli
Brian Gabrielli
JCJazmina L.G. Cruz
Jazmina L.G. Cruz
Immune checkpoint blockade (ICB) is now standard of care for several metastatic epithelial cancers and prolongs life expectancy for a significant fraction of patients. A hostile tumor microenvironment (TME) induced by intrinsic oncogenic signaling induces an immunosuppressive niche that protects the tumor cells, limiting the durability and efficacy of ICB therapies. Addition of receptor tyrosine kinase inhibitors (RTKi) as potential modulators of an unfavorable local immune environment has resulted in moderate life expectancy improvement. Though the combination strategy of ICB and RTKi has shown significantly better results compared to individual treatment, the benefits and adverse events are additive whereas synergy of benefit would be preferable. There is therefore a need to investigate the potential of inhibitors other than RTKs to reduce malignant cell survival while enhancing anti-tumor immunity. In the last five years, preclinical studies have focused on using small molecule inhibitors targeting cell cycle and DNA damage regulators such as CDK4/6, CHK1 and poly ADP ribosyl polymerase (PARP) to selectively kill tumor cells and enhance cytotoxic immune responses. This review provides a comprehensive overview of the available drugs that attenuate immunosuppression and overcome hostile TME that could be used to boost FDA-approved ICB efficacy in the near future.

28 July 2025
Verified
Thesis
Closed access
XLXuehan Lu
Xuehan Lu
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.